Japan’s contract drug rep ratio rose to 8.7% in FY2024 as the total number of regular reps continued to fall, the Japan Contract Sales Organization Association (JCSOA) reported in June. Amid industry downsizing, the roles and expectations placed on contract…
REGULATORY
Policy Veterans’ Group Advocates Drug Reimbursement at Actual Purchase Prices
An independent study group of policy veterans, dubbed Kusuri Mirai Juku, on October 27 proposed the stepwise introduction of a new system to reimburse drugs used by medical institutions at their purchase prices. If such system is introduced, medical institutions…
To read the full story
Related Article
- Policy Veterans’ Group Opposes Expansion of CEA Price Adjustments
June 13, 2025
- Policy Veterans’ Group Urges Japan to More than Double Minimum Drug Prices
February 21, 2025
- Policy Veterans’ Group Proposes Special Drug Price Rule for Antibiotics
October 3, 2024
- Policy Veterans’ Group Renews Call for Company-Proposed Pricing, Floats Support System for Biosimilars
November 15, 2023
- Discuss Multi-Faceted Evaluation of Drugs Ahead of Lecanemab Approval: Policy Veterans’ Group
May 10, 2023
- Policy Veterans’ Group Floats Proposal to Prevent Unprofitability to Stabilize Drug Supply
February 21, 2023
- Deloitte Proposes Pricing Schemes to Encourage Consolidation of Generic Makers
October 31, 2022
- Ex-Bureaucrats, Academics Trade Barbs over Macroeconomic Indexing; Will MOF Allow Rise in Drug Cost?
October 28, 2022
- Veterans’ Group Proposes Timely Drug Re-Pricing with Online Data, Reimbursement at Actual Purchase Prices
July 27, 2022
REGULATORY
- Novartis’ Radioligand Therapy, Other New Meds Up for Japan Panel Review on Aug. 22
August 12, 2025
- Japan Nears Approval for 1st Biosimilars of Actemra, Simponi, and Ranmark
August 12, 2025
- Japan Approves FY2026 Budget Guidelines, Natural Increase at 400 Billion Yen
August 12, 2025
- PMDA Flags New Potential Risks for RAS Agents and Others
August 12, 2025
- Japan Approves MSD’s 21-Valent Pneumococcal Vaccine
August 8, 2025
A recent conversation with a US biopharma senior director highlighted a critical talent gap: a strong demand for individuals with strategic management, critical thinking, and advanced business acumen-skills beyond traditional operational excellence. After the conversation, I rushed home and picked…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…